Several possible studies
Story checked
Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment (opens in a new tab)
news-medical.net · 2026-10-27
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment
news-medical.net · 2026-10-27
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedPatients with advanced lung cancer lived 56 percent longer without their disease progressing when radiotherapy was added to standard treatment.View evidenceHide evidence
As stated56 percent longer
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 6Not checkedThe finding came from initial results from the SARON trial, presented at the 2026 European Society for Medical Oncology Congress.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 6Not checkedThe Phase II randomized controlled trial enrolled 140 patients with oligometastatic non-small cell lung cancer and compared standard systemic therapy alone with standard therapy plus local consolidation radiotherapy.View evidenceHide evidence
As stated140 patients
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 6Not checkedAfter a median follow-up of 37.4 months, average progression-free survival was 13.9 months with radiotherapy versus 8.9 months with standard treatment alone.View evidenceHide evidence
As stated13.9 months vs 8.9 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 6Not checkedThe radiotherapy arm had fewer patients with progression of the initial sites of disease within 12 months, and the treatment was well tolerated without any significant reduction in quality of life.View evidenceHide evidence
As stated13% vs 39.5% within 12 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 6Not checkedOverall survival was similar between groups, with a median of 31 months in the radiotherapy arm and 28 months in the control arm.View evidenceHide evidence
As stated31 months vs 28 months
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref · 15 candidate papers
Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
Clinical & Experimental Metastasis · 2026 · PubMed
Radiotherapy alone for non-small cell lung carcinoma. Five-year disease-free survival and patterns of failure
Lung Cancer · 1995 · Crossref
Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.
Cancer Research and Treatment · 2026 · PubMed
Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)
Lung Cancer · 2023 · Crossref
Beyond local control: radiotherapy-immunotherapy combinations from in situ vaccination to systemic immune remodeling.
Frontiers in Genetics · 2026 · PubMed